Hengrui–Elevar HCC Combo Rejected Again
The FDA issued a third complete response letter for camrelizumab plus rivoceranib as first-line treatment for unresectable or metastatic hepatocellular carcinoma. The July 10 decision cited cGMP deficiencies at a manufacturing site listed in…
